Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 64 (6), 663-7

Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics


Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics

Scott W Woods. J Clin Psychiatry.


Background: Several clinical and research applications require an estimation of therapeutic dose equivalence across antipsychotic medications. Since the advent of the newer atypical antipsychotics, new dose equivalent estimations have been needed.

Method: The reported minimum effective dose was identified for each newer atypical antipsychotic medication and for haloperidol across all available fixed-dose placebo-controlled studies. Reported minimum effective dose equivalence ratios to haloperidol were then converted to chlorpromazine equivalents using the "2 mg of haloperidol equals 100 mg of chlorpromazine" convention.

Data sources and study selection: To identify the fixed-dose studies, the following sources were searched until June 2002: MEDLINE, the bibliographies of identified reports, published meta-analyses and reviews, Cochrane reviews, Freedom of Information Act material available from the Food and Drug Administration, and abstracts from several scientific meetings from 1997 to 2002.

Results: Doses equivalent to 100 mg/day of chlorpromazine were 2 mg/day for risperidone, 5 mg/day for olanzapine, 75 mg/day for quetiapine, 60 mg/day for ziprasidone, and 7.5 mg/day for aripiprazole.

Conclusion: These equivalency estimates may be useful for clinical and research purposes. The source of the dose equivalency estimation is evidence-based and consistent across medication.

Similar articles

  • Olanzapine Versus Other Atypical Antipsychotics for Schizophrenia
    K Komossa et al. Cochrane Database Syst Rev (3), CD006654. PMID 20238348. - Review
    Olanzapine may be a somewhat more efficacious drug than some other second generation antipsychotic drugs. This small superiority in efficacy needs to be weighed against a …
  • Risperidone Versus Other Atypical Antipsychotics for Schizophrenia
    K Komossa et al. Cochrane Database Syst Rev (1), CD006626. PMID 21249678. - Review
    Risperidone seems to produce somewhat more extrapyramidal side effects and clearly more prolactin increase than most other SGAs. It may also differ from other compounds i …
  • Atypical Antipsychotics for Psychosis in Adolescents
    A Kumar et al. Cochrane Database Syst Rev (10), CD009582. PMID 24129841. - Review
    No convincing evidence suggests that atypical antipsychotic medications are superior to typical medications for the treatment of adolescents with psychosis. However, atyp …
  • Ziprasidone: A New Atypical Antipsychotic
    PE Keck Jr et al. Expert Opin Pharmacother 2 (6), 1033-42. PMID 11585006. - Review
    This paper reviews the clinical pharmacology, efficacy and safety of the new atypical antipsychotic, ziprasidone. All published citations regarding ziprasidone were retri …
  • Quetiapine Versus Other Atypical Antipsychotics for Schizophrenia
    L Asmal et al. Cochrane Database Syst Rev (11), CD006625. PMID 24249315. - Review
    Available evidence from trials suggests that most people who start quetiapine stop taking it within a few weeks (around 60%). Comparisons with amisulpride, sertindole and …
See all similar articles

Cited by 548 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources